02162 KEYMED BIO-B
- 33.200
- -0.900-2.64%
KEYMED BIO-B News
Featured announcements | Xiaomi Q1's adjusted net profit doubled year on year; Bilibili Q1's adjusted loss narrowed 56% year on year
Shell's revenue for the first quarter was 16.4 billion yuan, down 19.2% year on year; NetEase's first quarter revenue was 26.9 billion yuan, up 7.2% year on year; net profit was 7.6 billion yuan, up 13% year on year.
Conoa-B (02162.HK): Spuquipimab injection included in the priority review and approval process for the treatment of chronic sinusitis with nasal polyps
Glonghui, May 23 | Conoa-B (02162.HK) announced that recently, after review by the Drug Evaluation Center (“Drug Evaluation Center”) of the State Drug Administration, it was agreed to include spoximab injections in the priority review process for the treatment of chronic sinusitis with nasal polyps in accordance with the scope of priority review “(1) drugs in short supply, innovative drugs for the prevention and treatment of diseases such as major infectious diseases and rare diseases”. According to reports, spoximab (R&D code CM310) is an efficient, humanized antibody targeting the interleukin 4 receptor alpha subunit (IL-4Rα). It is the first domestically produced and
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Huayuan Securities: Conoa-B (02162.HK) CM310 single product is about to be approved, and the innovation pipeline is actively promoting the initial purchase
Huayuan Securities released a research report saying that considering that the company's core pipeline is about to be approved, the research pipeline is progressing positively. Coverage was given for the first time, giving the company Conoa-B (02162.HK) a “buy” rating. The estimated revenue for 2024-2026 is 1.19, 5.78, and 1,272 billion yuan, respectively. Connoah was founded in 2016 and listed on the main board of the Hong Kong Stock Exchange in 2021. The company focuses on itself and the field of oncology, and efficiently promotes clinical research on a number of innovative products. The core product IL4Rα monoclonal antibody CM310 is expected to be approved for launch in China this year. Other innovative pipelines under development have differentiated layout and progress
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Stock prices are falling on the eve of commercialization. When will Conoa-B (02162) remove the mountain Sanofi?
On April 25, Sanofi released its 2024 Q1 financial report. Of its total revenue of 10.464 billion euros, Dipriumab, the core product of the free free pipeline, contributed 2,835 billion euros, equivalent to 21.98 billion yuan. According to the annual report previously disclosed by Sanofi, the total global sales volume of the drug reached 11.5 billion US dollars in 2023. This sales volume is clearly out of reach for the domestic IL4R monoclonal circuit Gemini Conoa-B (02162) and Concord Biotech (CNTB.US), which have yet to commercialize their products. But after years of research and development, Connor, one of the twins
Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA
Keymed Biosciences (HKG:2162) said the National Medical Products Administration accepted its new drug application for Stapokibart injection for seasonal allergic rhinitis, according to a Tuesday filin
Conoa-B (02162.HK): The application for marketing licensing of drugs with spoximab injections to treat seasonal allergic rhinitis was accepted by the State Drug Administration
On April 30, Gelonghui | Conoa-B (02162.HK) issued an announcement. The application for marketing licensing of drugs with spiquimab injections to treat seasonal allergic rhinitis has recently been accepted by the China Drug Administration (“State Drug Administration”). This report is based on a multi-center, randomized, double-blind, placebo-controlled phase III study, which is mainly used to confirm the efficacy and safety of spiquivizumab injections for patients with seasonal allergic rhinitis in adults with poor control of nasal glucocorticoids or other treatments. The study results showed positive results from phase III clinical trial data, the main end point
Conoa-B (02162.HK): CM310 SAR phase III clinically successful product is expected to be approved within the year
Company News On April 28, the company announced that the phase III clinical trial of allergic rhinitis (SAR) during the CM310 treatment season has completed data deconstruction and statistical analysis of double-blind treatment period data, and clinical data has reached the main end point. Comments about CM3
Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points
Keymed Biosciences (HKG:2162) said their Class 1 innovative drug CM310 for treating seasonal allergic rhinitis achieved its primary endpoints in a Phase III clinical study, according to a Sunday filin
Conoa-B (02162.HK): CM310 will soon be commercialized with differentiated pipeline layout in the early stages
Core view: (Unless otherwise specified, the following currencies are all RMB) The company issued the 2023 annual report performance announcement: revenue of 354 million yuan (+254% year over year, the following are all year-on-year caliber), mainly to authorize CMG to AZ
Conoa-B (02162): Phase III clinical trial of spoxibimab injection to treat seasonal allergic rhinitis reached the main end
Conoa-B (02162) issued an announcement. The company is pleased to announce that its Class 1 new drug, CM310, recombinant humanized monogram...
Conoa-B (2162.HK): Exclusive opportunity to reach the end of phase III allergic rhinitis
On April 28, the company revealed that the phase III clinical trial of sepcibimab for SAR had reached the main end point. On April 28, the company revealed that the phase III clinical trial of sepcibimab for SAR had reached the main end point. Among 108 subjects, the drug rTNSS
康諾亞-B：2023年度報告
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
Changes in Hong Kong stocks | Conoa-B (02162) rose more than 6%, CM310 has submitted a listing application, and the company is welcoming the new commercialization cycle
Conoa-B (02162) rose more than 6%. As of press release, it had risen 6.17% to HK$30.95, with a turnover of HK$8.98,800.
Tencent recorded the biggest one-day increase in 10 months! The public offering group went south, and Zhang Kun and his team “overmatched” Hong Kong stocks
In the context of public fund giants collectively increasing their positions, Tencent Holdings recorded the biggest one-day increase in the last 10 months.
A quick look at the Hong Kong market | The three major indices have risen one after another. Technet stocks have generally risen, Tencent and Meituan have risen by more than 5%; Ideal has fallen by more than 8%
Many coal stocks fell sharply; Mongolian coking coal and China Coal Energy fell more than 6%; petroleum stocks fell, CNOOC Services fell more than 3%, and CNPC fell nearly 3%.
Changes in Hong Kong stocks | Conoa-B (02162) rose more than 7% in the afternoon to complete a clinical trial of a drug to treat advanced solid tumors, completed the first case of the first test subject
Conoa-B (02162) rose more than 7% in the afternoon. As of press release, it was up 6.74% to HK$29.3, with a turnover of HK$404.85,500.
Analysis
Price Target
No Data
